Announcement Executive Order no. 226 of 15 March 2007 regarding issuers' obligations According to Executive Order no. 226 of 15 March 2007 regarding issuers' obligations, we hereby notify that on 01.06.2007 the total share capital of NeuroSearch A/S amounts to DKK 248,903,420 distributed on 12,445,171 shares. Each share of DKK 1 carries one vote at the general meetings. Asger Aamund Chairman of the Board Contact persons:Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications Phone: +45 4017 5103 NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen Stock Exchange (NEUR). Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channel and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises nine clinical development programmes: ACR16 within Huntington's disease (Phase III preparation), tesofensine within obesity/type 2 diabetes (Phase II), NS2359 within depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 within epilepsy and pain (Phase II), ABT-894 within ADHD (Phase II) and pain (Phase I) in partnership with Abbott, ACR16 within schizophrenia (Phase I) in partnership with Astellas, ACR325 within psychoses such as bipolar disorder (Phase I) and ABT-107 for the treatment of various CNS diseases (Phase I) in collaboration with Abbott. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and has equity interests in several biotech companies.
Executive Order no. 226 of 15 March 2007 regarding issuers' obligations
| Source: NTG Nordic Transport Group A/S
Attachments
